IBM Life Sciences

Join us in discussing the latest news, research, and industry insights surrounding the Life Sciences Industry from a top-level view.

Cognitive Computing: Enabling breakthrough discoveries for the life sciences industry

Life sciences companies are embracing the power of cognitive computing to fuel breakthrough discoveries and better manage the tsunami of data they are looking to mine for insights.  In our complex healthcare ecosystem, volumes of seemingly unrelated, disparate data need to be brought together to deliver actionable insights. As more and more data is becoming […]

Continue reading

A game changer for life sciences

Cognitive computing for life sciences can be a game changer. Here’s why. Over the last few weeks the papers have been filled with stories about computers beating the very best in the world at the very hardest board game in the world. Now I don’t profess to be knowledgeable about this ancient strategy game or […]

Continue reading

Learn more about IBM


IBM Solutions and Services for Healthcare

Transform your organization’s value with access to new and unprecedented amounts of data - across populations and at the level of the individual - for deeper insight, personalization and earlier interventions.

Join the Conversation


Hyper Acceleration of Personalized Medicine: Part 2

Part 1 of this blog provided an overview of drivers accelerating the transformation of healthcare to personalized medicine.  This blog provides more detail on how IBM is helping facilitate this transformation. IBM’s role in accelerating discovery Vendors like IBM have key roles in facilitating this transformation. From investing in technologies including IBM Watson, cloud, Spark, […]

Continue reading

Hyper Acceleration of Personalized Medicine: Part 1

In a dozen years since the completion of the Human Genome Project, the healthcare industry is moving rapidly to develop treatments that can be tailored to the unique genetic code of each patient.  One catalyst for this transformation to personalized treatment is the Next Generation Sequencing (NGS) systems.  The first human genome sequenced cost US […]

Continue reading

AdvaMed 2015: IBM Presence

AdvaMed, is the leading MedTech conference in North America bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, and innovative technology showcasing world class educational opportunities and networking. IBM has a sponsored presence at this event. Lauren O’Donnell, IBM Life Sciences, Global Manager and Vice-President, will moderate a […]

Continue reading

Innovating in the age of ecosystems

Persistent disruptive forces in life sciences are threatening traditional business models over the medium to long term. New technologies are driving radical disruption, value chains are fragmenting and industries are converging. While high rates of return and strong performance may have masked these forces in the past, today they need to be recognized and addressed […]

Continue reading

A C-Suite Perspective on Increasing the Velocity of Successful Transformation for the Pharmaceutical Industry: An interview with Dr. Linda A. Hill, Professor at the Harvard Business School

Preface: As the pharmaceutical industry continues to make progress at transformation, what ground-breaking strategies could help accelerate its success? With Apple Computer’s recent attainment as the top ranked Fortune Most Admired Company* for an unprecedented eight consecutive years as an inspirational guidepost, this Q&A with Dr. Linda A. Hill explains how the industry could potentially […]

Continue reading

A C-Suite Perspective on Increasing the Velocity of Successful Transformation for the Pharmaceutical Industry: An interview with Dr. David-Alexandre Gros, Executive Vice President, Chief Strategy Officer at Sanofi

Preface: As the pharmaceutical industry continues to make progress against its transformation, what ground-breaking strategies are the firms deploying? Similar to how Apple Computer recently chalked up the top ranking of Fortune’s Most Admired Company* for an unprecedented eight consecutive years; this Q&A with Dr. David-Alexandre Gros, Executive Vice President and Chief Strategy Officer of […]

Continue reading

Using Hadoop to Manage your Data and Deliver Optimal Patient Care

Economic, demographic and technological forces are driving an unprecedented transformation of the healthcare industry. Underlying this transformation is the explosion of data at a rate such that it is growing faster than any healthcare organization can consume it. Gartner analysts predict that unstructured data will grow 800% over the next five years and 80% of […]

Continue reading

Revisiting the wisdom of the cloud for life sciences

Current industry challenges along with disruptions from forces such as the mobile revolution; hyper-digitization and the social media explosion are creating a need for even greater innovation and agility in the life sciences industry. How can new technologies such as cloud play a fundamental role in helping the life sciences industry to become more collaborative, […]

Continue reading

A C-Suite Perspective on the Top 3 Turn-Around Moves that Pharma Executives Should Consider for 2015: An interview with Wayne Yetter, Board Member of Special Diversified Opportunities Inc., InfuSystem, Inc. and MTG Biotherapeutics

Preface: Will pharma ever reclaim the success that it once had nearly 25 years ago? Consider Merck in 1990. After overtaking IBM as Fortune’s overall “Most Admired Company” for four years in a row, Merck’s reputation helped to secure an application to acceptance ratio for its sales rep positions of 70:1, compared to Harvard Business […]

Continue reading

A C-Suite Perspective on The Top 3 Turn-Around Moves that Pharma Executives Should Consider for 2015: An interview with Jay Galeota, Chief Strategy and Business Development Officer and President of Emerging Businesses of Merck &Co., Inc.

Preface: Will pharma ever reclaim the success that it once had nearly 25 years ago? Consider Merck in 1990. After overtaking IBM as Fortune’s overall “Most Admired Company” for four years in a row (on its way to seven  consecutive years with this honor), Merck’s reputation helped to secure an application to acceptance ratio for […]

Continue reading